Calcineurin inhibitors for topical therapy in psoriasis;Calcineurininhibitoren zur topischen therapie der psoriasis

Hautarzt

Volumn 57, Issue 8, 2006, Pages 685-689

  Wohlrab, J ^a  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

Calcineurin inhibitors; Pimecrolimus; Psoriasis; Tacrolimus; Topical therapy

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIPSORIASIS AGENT; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CYCLOSPORIN A; CYTOKINE; IMMUNOPHILIN; INTERLEUKIN 2; PIMECROLIMUS; PROTEIN KINASE (CALCIUM,CALMODULIN) II; TACROLIMUS;

ARTICLE; CELL ACTIVATION; CELL NUCLEUS; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG SOLUBILITY; ENZYME ACTIVATION; GRANULOCYTE; HUMAN; LIPOPHILICITY; MAST CELL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PSORIASIS; T LYMPHOCYTE; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; CALCINEURIN; CELL DIVISION; CYCLOSPORINE; CYTOKINES; DERMATOLOGIC AGENTS; GENE EXPRESSION REGULATION; GRANULOCYTES; HUMANS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MAST CELLS; PILOT PROJECTS; PSORIASIS; T-LYMPHOCYTES; TACROLIMUS;

EID: 33748951910     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-006-1185-9     Document Type: Article

References (37)

1. Amichai B (2004) Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream. J Eur Acad Dermatol Venereol 18: 742-743
2. Bigby M (2005) Pimecrolimus and tacrolimus for the treatment of intertriginous and facial psoriasis: are they effective? Arch Dermatol 141: 1152-1153
3. Billich A, Vyplel H, Grassberger M et al. (2005) Novel cyclosporin derivates featuring enhanced skin penetration despite increased molecular weight. Bioorg Med Chem 13: 3157-3167
4. Bousema MT, Tank B, Heule F et al. (1990) Placebo-controlled study of psoriasis patients treated topically with a 10% cyclosporine gel. J Am Acad Dermatol 22:126-127
5. bu-Elmagd K, van TD, Jegasothy BV, Ackerman CD et al. (1991) FK 506: a new therapeutic agent for severe recalcitrant psoriasis. Transplant Proc 23: 3322-3324
6. Choi HK, Flynn GL, Amidon GL (1995) Percutaneous absorption and dermal delivery of cyclosporin A. J Pharm Sci 84: 581-583
7. Erdogan M, Wright JR Jr, McAlister VC (2002) Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model. Br J Dermatol 146: 964-967
8. Freeman AK, Linowski GJ, Brady C et al. (2003) Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 48: 564-568
9. Gottlieb AB, Griffiths CE, Ho VC et al. (2005) Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. Br J Dermatol 152: 1219-1227
10. Grassberger M, Steinhoff M, Schneider D, Luger TA (2004) Pimecrolimus - an anti-inflammatory drug targeting the skin. Exp Dermatol 13: 721-730
11. Gribetz C, Ling M, Lebwohl M et al. (2004) Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 51: 731-738
12. Griffiths CE, Powles AV, Baker BS et al. (1987) Topical cyclosporin and psoriasis. Lancet 1: 806
13. Gupta AK, Chow M (2003) Pimecrolimus: a review. J Eur Acad Dermatol Venereol 17: 493-503
14. Gupta AK, Fisher GJ, Elder JT et al. (1989) Topical cyclosporine A inhibits the phorbol ester induced hyperplastic inflammatory response but not protein kinase C activation in mouse epidermis. J Invest Dermatol 93: 379-386
15. Hermann RC, Taylor RS, Ellis CN et al. (1988) Topical ciclosporin for psoriasis: in vitro skin penetration and clinical study. Skin Pharmacol 1: 246-249
16. Jahn K (2002) Moderne galenische Zubereitungen zur dermalen Anwendung von Ciclosporin A und Mycophenolatmofetil. Shaker, Aachen
17. Kroft EB, Erceg A, Maimets K et al. (2005) Tacrolimus ointment for the treatment of severe facial plaque psoriasis. J Eur Acad Dermatol Venereol 19: 249-251
18. Lebwohl M, Freeman A, Chapman MS et al. (2005) Proven efficacy of tacrolimus for facial and intertriginous psoriasis. Arch Dermatol 141: 1154
19. Lebwohl M, Freeman AK, Chapman MS et al. (2004) Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 51: 723-730
20. Liu H, Li S, Wang Y et al. (2006) Effect of vehicles and enhancers on the topical delivery of cyclosporin A. Int J Pharm 311: 182-186
21. Mansouri P, Farshi S (2006) Pimecrolimus 1 percent cream in the treatment of psoriasis in a child. Dermatol Online J 12: 7
22. Marsland AM, Griffiths CE (2002) The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 12: 618-622
23. Mrowietz U, Graeber M, Brautigam M et al. (1998) The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 139: 992-996
24. Mrowietz U, Wustlich S, Hoexter G et al. (2003) An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol 83: 351-353
25. Ortonne JP, van de Kerkhof PC, Prinz JC et al. (2006) 0.3% Tacrolimus gel and 0.5% Tacrolimus cream show efficacy in mild to moderate plaque psoriasis: results of a randomized, open-label, observer-blinded study. Acta Derm Venereol 86: 29-33
26. Pharmazeutisches Laboratorium des "Neuen Rezeptur-Formularium" (2004) Standardisierte Rezepturen. Govi, Eschborn
27. Rallis E, Nasiopoulou A, Kouskoukis C et al. (2005) Successful treatment of genital and facial psoriasis with tacrolimus ointment 0.1%. Drugs Exp Clin Res 31: 141-145
28. Rappersberger K, Komar M, Ebelin ME et al. (2002) Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 119: 876-887
29. Scheinfeld N (2004) The use of topical tacrolimus and pimecrolimus to treat psoriasis: a review. Dermatol Online J 10: 3
30. Schulze HJ, Mahrle G, Steigleder GK (1990) Topical cyclosporin A in psoriasis. Br J Dermatol 122: 113-114
31. Steele JA, Choi C, Kwong PC (2005) Topical tacrolimus in the treatment of inverse psoriasis in children. J Am Acad Dermatol 53: 713-716
32. The European FK 506 Multicentre Psoriasis Study Group (1996) Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol 132: 419-423
33. Tosti A, Guerra L, Bardazzi F, Lanzarini M (1990) Topical ciclosporin in nail psoriasis. Dermatologica 180: 110
34. Wolff K (2004) Current concepts and review of pimecrolimus in the treatment of psoriasis. Dermatol Clin 22: 461-465
35. Yamamoto T, Nishioka K (2000) Topical tacrolimus is effective for facial lesions of psoriasis. Acta Derm Venereol 80: 451
36. Yocum DE (1996) Cyclosporine, FK-506, rapamycin, and other immunomodulators. Rheum Dis Clin North Am 22: 133-154
37. Zonneveld IM, Rubins A, Jablonska S et al. (1998) Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 134: 1101-1102